CA-HYPERICE
15.9.2022 12:02:01 CEST | Business Wire | Press release
Hyperice, a global high-performance wellness brand, today announced two new products within their heat therapy category, Venom Go and Venom 2, alongside HyperHeat™ technology for the fastest, most consistent and even distribution of heat to relieve sore, stiff muscles and promote wellness. Venom Go advances the capabilities of the Venom line further with the ability to deliver heat and vibration spot treatment in more areas, such as the neck, shoulder, upper and lower back, calf and forearm. Designed with flexibility in mind, Venom Go can be utilized in more environments than ever before, with unmatched versatility and customizations, delivering instant muscle relief wherever the body needs it most. Venom 2 is the most advanced heat and massage wrap on the market and carries on the legacy built by the original Venom line, which revolutionized the traditional heating pad for consumers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220915005442/en/
"The new Venom Go allows me to be even more targeted with muscle recovery to keep me moving at my best so I can help others move at their best too.” -Robin Arzón, Hyperice Athlete-Investor, and Peloton Vice President of Fitness Programming. (Photo: Business Wire)
“The new Venom Go is a revolutionary product for us as it widens the application of our Venom technology and addresses the need for a powerful heat and vibration solution for spot treatment,” said Jim Huether, CEO of Hyperice. “It’s been six years since the debut of heat and vibration technology from Hyperice, we’ve now significantly enhanced the Venom user experience and added our patented HyperHeat™ technology, all while staying true to the core elements of the original product that made people fall in love with it. The Venom line is one of our fastest growing product lines, and we expect this trend to continue in the U.S. and throughout the world.”
INTRODUCING VENOM GO
The Venom Go is a heat and vibration wearable that consists of a control pod that magnetically connects to an adhesive pad and is applied directly to the skin. Venom Go pads are reusable approximately 20 to 40 times each (depending on placement on body and any sweat, lotion or oil that may be on the skin) and cover 13.5 square inches, allowing users to receive direct treatment to more areas of the body than ever before. Users can select from 3 levels of heat and 3 levels of vibration via easy to use button control on the pod. Sore and stiff muscles can now receive instant treatment, with Venom Go reaching up to 113℉ (45°C) in 90 seconds after applied to the skin - or just 20 seconds prior to being applied to the skin.
The Venom Go control pod and pad weighs a mere 0.2 lbs, and holds a battery life of up to 60 minutes on a full charge, with a standard session running for 10 minutes. The Venom Go is charged via USB connection and is TSA approved for convenient use while traveling. Utilizing Bluetooth connectivity, the Venom Go is controlled via the Hyperice App, with users having the ability to sync multiple pods to deliver tailored spot treatments across different areas of the body at once for a unique heat and vibration therapy experience.
“Recovery plays a key role in performing your best every day,” said Robin Arzón, Hyperice Athlete-Investor, and Peloton Vice President of Fitness Programming. “Venom has always been a staple product in my warmup and recovery routines. Vibration and heat are both critical components in the equation. The new Venom Go allows me to be even more targeted with muscle recovery to keep me moving at my best so I can help others move at their best too.”
The introduction of the Venom Go comes on the heels of the introduction of the Normatec Go (currently only available in the US), and now provides a holistic suite of products within Hyperice’s Go series (Hypersphere Mini, Hypervolt Go 2, Vyper Go, Normatec Go). Portable and mobile adaptations of each product line offer users maximum flexibility to experience the benefits of warm up and recovery technology in more places, and at more price points, than ever before.
“With the Venom Go, users will be able to experience the same benefits they have grown to know and love in the Venom line, but in many more targeted areas for relief,” added Huether. “This product is amazing for anyone with soreness, stiffness or pain in targeted areas, and furthers our mission to help as many people as possible improve their daily lives through recovery and movement.”
INTRODUCING VENOM 2
The Venom 2, which comes in versions for the back, leg and shoulder (left or right), has more-than-doubled its treatment area, increasing the overall heating surface by 111% (94 square inches), and is encased in a new silicone surface for easier cleaning. Venom 2 delivers up to a three-hour battery life on a full charge, and heats to 131℉ (55°C) in just one minute, which is four times faster than the original Venom, and six times faster than a traditional heating pad. Users will also experience a lighter version of the Venom, as the weight drops by more than 23% from the original version, now weighing just two lbs.
“Heat therapy is such a critical component of my routine, from preparing for a game and getting my shoulder loose, to treating sore muscles in my arm between practices,” said Patrick Mahomes, Hyperice Athlete-Investor and Super Bowl Champion. “From pregame, to the training facility and home, the Venom line allows me to optimize my performance. The new Venom 2 improves the experience and I know will be a popular tool in the locker room.”
“As a footballer, I need to ensure that my body is ready to endure the rigors that come with a 90-minute match,” said Erling Haaland, Hyperice Athlete-Investor and global footballer. “Heat therapy is very important in ensuring my body is properly prepared and ready to go ahead of training or kickoff, and equally important in the time between match-days. I’m always looking for ways to give myself a competitive edge, and with Venom 2’s heating time, I feel the benefits quicker than ever before, and can be ready to take the pitch faster with my body ready to go.”
Through Bluetooth® connectivity, the Venom 2 is controlled via the Hyperice App, unlocking more routines to maximize and customize time, heat and vibration while using the device.
HYPERHEAT™ TECHNOLOGY
With the launch of Venom Go and the Venom 2, Hyperice also introduces their new HyperHeat™ technology which delivers a faster, more consistent distribution of heat across a greater surface area, allowing for a more premium experience for users.
“In 2015 we were getting requests from NBA players for a product that could heat the body pregame and keep the body warm when they came out of the game. Our answer was the Venom, the first heat and vibration wearable device, released in 2017,” said Anthony Katz, Hyperice Founder. “Over the past five years, the user base for the Venom has expanded far beyond performance athletes to everyday people who use the Venom to manage pain and soreness. The Venom 2 is a complete redesign and upgrade from the original model- every aspect of the product and experience have been improved.“
The Venom Go ($149; £159; €175) and Venom 2 line ($249; £269; €299) are available in North America as well as globally across all countries and regions where Hyperice is sold. For more information, please visit hyperice.com country-specific sites.
About Hyperice
Hyperice is a technology-driven company with a giant mission, to help everyone on Earth move and live better. For more than a decade, Hyperice has led a global movement at the confluence of recovery and wellness, specializing in percussion (Hypervolt line), dynamic air compression (Normatec line), vibration (Vyper and Hypersphere lines), thermal technology (Venom line), mind technology (Core by Hyperice) and contrast therapy (Hyperice X). Now, as a holistic high-performance wellness brand, Hyperice is designed for all - from the most elite athletes, leagues and teams to consumers everywhere looking to unlock the best version of themselves to help them do what they love, more. Recognized as one of Fast Company’s Most Innovative Companies, Hyperice has applied its technology and know-how to industries including fitness, hospitality, healthcare, massage, physical therapy, sports performance and workplace wellness on a global scale. Hyperice’s transformative acquisitions of Normatec, RecoverX and Core have helped to accelerate its innovation agenda as it enters its next stage of global growth. For more information, visit the newly redesigned hyperice.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005442/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
